Genetic Technologies (GENE) Stock Price, News & Analysis

Company Overview

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Key Stats

• Today's Range: $0.77 to $0.77
• 50-Day Range: $0.77 to $0.77
• 52-Week Range: $0.67 to $3.77
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $3.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GENE Stock Analysis - Frequently Asked Questions

When did Genetic Technologies' stock split?

Genetic Technologies shares reverse split on Monday, December 4th 2023.The 1-5 reverse split was announced on Monday, December 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genetic Technologies investors own include Netflix (NFLX), Plug Power (PLUG), Meta Platforms (META), OPKO Health (OPK), Nokia (NOK), Novavax (NVAX) and iBio (IBIO).

Company Calendar

• Today: 10/14/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GENE
• CIK: 1166272
• Web: www.gtgcorporate.com
• Phone: (138) 412-7000
• Fax: 011-61-3-8412-7040
• Employees: 50
• Year Founded: 1989

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 0.88
• Quick Ratio: 0.83

Sales & Book Value

• Annual Sales: $7.66 million
• Price / Sales: 0.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.25 per share
• Price / Book: 3.06

Miscellaneous

• Outstanding Shares: 4,407,000
• Free Float: 4,534,000
• Market Cap: $3.37 million
• Optionable: Optionable
• Beta: 1.12